Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsSector newsTweets 

Sanofi to Cut 1,500-2,000 Jobs in France - Report

share with twitter share with LinkedIn share with facebook
share via e-mail
09/15/2012 | 02:11pm CET

French pharmaceutical giant Sanofi SA (SAN.FR, SNY) will disclose cuts of between 1,500 and 2,000 jobs in France on Sept. 25, French newspaper Le Figaro reported Saturday, without citing sources.

The company plans to reduce its 28,000 payroll in France mainly through attrition, the newspaper said.

In July, Sanofi had said it planned to cut jobs at two French units in a bid to preserve the company's profitability, which has been put at risk by recent patent expirations and the economic recession in most of Europe. The company had said it would detail the job cuts in September.

At the time, French Industry Minister Arnaud Montebourg had criticized the company and said he wouldn't tolerate when profitable companies slash jobs.

A Sanofi spokesman didn't return a phone call seeking comments.

Newspaper Web site: http://www.lefigaro.fr

Write to Inti Landauro at inti.landauro@dowjones.com.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
12:22a Sanofi’s M&A misses frustrate some investors in drugmaker
01/23 SANOFI : Disclosure of trading in own shares
01/23 Agenda Out for Pharmaceutical Freeze Drying 2017 Summit Featuring Pfizer, Boe..
01/23 SANOFI : ​Availability of the Pre-quarterly Results Communication
01/23 SANOFI : Availability of the Pre-quarterly Results Communication
01/21 Agenda Released for Pharmaceutical Freeze Drying 2017 Summit Featuring Pfizer..
01/19 SANOFI : and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune ..
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
More news
Sector news : Pharmaceuticals - NEC
01:30pDJJOHNSON & JOHNSON : Revenue Rises But Forecast Disappoints
01:17p JOHNSON & JOHNSON : sales growth disappoints; Co mulling options for diabetes un..
12:35a U.S. reaches settlement with Endo on pay-for-delay charges
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/23 Opportunities In China's Healthcare Market
01/23 Sanofi teams up with Enteris BioPharma to develop oral T2D med
01/20 Pharma bigwigs acknowledge challenges with perceptions of pricing as Trump pr..
01/19 Kaleo undeterred by Mylan's trevails over EpiPen pricing; employing same cont..
01/19 Reasons A Regeneron Pharmaceuticals Takeover Is Unlikely
Financials (€)
Sales 2016 36 742 M
EBIT 2016 9 205 M
Net income 2016 5 242 M
Debt 2016 6 114 M
Yield 2016 3,92%
P/E ratio 2016 16,45
P/E ratio 2017 14,73
EV / Sales 2016 2,80x
EV / Sales 2017 2,79x
Capitalization 96 695 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 81,1 €
Spread / Average Target 8,3%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.66%103 847
JOHNSON & JOHNSON-1.13%309 896
ROCHE HOLDING LTD.0.39%200 025
PFIZER INC.-3.14%190 910
NOVARTIS AG-4.32%183 809
MERCK & CO., INC.4.99%170 419
More Results